Sam Brusco, Associate Editor07.25.23
Baxter announced that Vantive will become the name of its proposed Renal Care and Acute Therapies businesses spinoff.
Vantive is expected to launch as an independent, publicly traded company by July 2024, according to Baxter.
“Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as CEO of the new company upon spinoff. “The Vantive name reflects our dedicated employees’ steadfast commitment to patients and our passion for helping them lead full and meaningful lives in partnership with our customers. We are eager to continue collaborating with the kidney and critical care communities as we work to transform care globally.”
Vantive carries Baxter’s almost 70-year legacy as a kidney disease and organ support company. Vantive aims to drive meaningful change in kidney care and organ support through innovative tech, digital connectivity, and services.
The logo and visual identity will be revealed at a later date. Until the proposed separation in 2024, the Kidney Care business will continue to operate as Baxter.
Baxter began slimming down its portfolio with the proposed sale of its biopharma unit to Advent International in May.
Vantive is expected to launch as an independent, publicly traded company by July 2024, according to Baxter.
“Announcing the Vantive name is a critical milestone in our journey to becoming an independent company focused solely on therapies for kidney disease and other vital organ support,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as CEO of the new company upon spinoff. “The Vantive name reflects our dedicated employees’ steadfast commitment to patients and our passion for helping them lead full and meaningful lives in partnership with our customers. We are eager to continue collaborating with the kidney and critical care communities as we work to transform care globally.”
Vantive carries Baxter’s almost 70-year legacy as a kidney disease and organ support company. Vantive aims to drive meaningful change in kidney care and organ support through innovative tech, digital connectivity, and services.
The logo and visual identity will be revealed at a later date. Until the proposed separation in 2024, the Kidney Care business will continue to operate as Baxter.
Baxter began slimming down its portfolio with the proposed sale of its biopharma unit to Advent International in May.